Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Íåâðîëîãèÿ è íåéðîõèðóðãèÿ

Íåâðîëîãèÿ è íåéðîõèðóðãèÿ Ôîðóìû: Ôîðóì äëÿ îáùåíèÿ âðà÷åé íåâðîëîãîâ è íåéðîõèðóðãîâ, Ìàíóàëüíàÿ òåðàïèÿ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #16  
Ñòàðûé 24.06.2018, 22:21
annadrobitova annadrobitova âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.06.2011
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,607
Ñêàçàë(à) ñïàñèáî: 17
Ïîáëàãîäàðèëè 1,149 ðàç(à) çà 1,121 ñîîáùåíèé
annadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñ ìèêðîýëåìåíòàìè ïîðÿäîê
Íà ÝÝÃ îò 26.04 ýïèàêòèâíîñòè íå óâèäåëà
Îòâåòèòü ñ öèòèðîâàíèåì
  #17  
Ñòàðûé 24.06.2018, 22:22
annadrobitova annadrobitova âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.06.2011
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,607
Ñêàçàë(à) ñïàñèáî: 17
Ïîáëàãîäàðèëè 1,149 ðàç(à) çà 1,121 ñîîáùåíèé
annadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
âîñïîëüçóéòåñü ïåðåâîä÷èêîì

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Vad îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #18  
Ñòàðûé 25.06.2018, 19:54
AlenaP2018 AlenaP2018 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 21.06.2018
Ãîðîä: Åêàòåðòíáóðã
Ñîîáùåíèé: 13
Ñêàçàë(à) ñïàñèáî: 2
AlenaP2018 *
Öèòàòà:
Ñîîáùåíèå îò annadrobitova Ïîñìîòðåòü ñîîáùåíèå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
âîñïîëüçóéòåñü ïåðåâîä÷èêîì
Ñïàñèáî çà ññûëêó,ïðî÷èòàëè.×èòàëè â èíòåðíåòå àíàëîãè÷íûå îïèñàíèÿ êîãäà ïîñòàâèëè ýòîò äèàãíîç Àà ïîä âîïðîñ.Êàêèå èññëåäîâàíèÿ åùå ìîæíî ïðîéòè äëÿ èñêëþ÷åíèÿ èëè ïîäòâåðæäåíèÿ ýòîãî äèàãíîçà?
Îòâåòèòü ñ öèòèðîâàíèåì
  #19  
Ñòàðûé 25.06.2018, 20:14
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,358
Ïîáëàãîäàðèëè 33,212 ðàç(à) çà 31,562 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
êàê æå âû ÷èòàëè/ïîíÿëè, åñëè çàäàåòå òàêèå âîïðîñû, êîãäà â òåêñòå:

Molecular genetic testing for mutations in the ATP1A3 gene is available on a clinical basis via individual targeted gene sequencing or as part of larger gene panels. Increasingly, ATP1A3 mutations are identified in the context of clinical exome sequencing.

Öèòàòà:
Ñîîáùåíèå îò annadrobitova Ïîñìîòðåòü ñîîáùåíèå
Îáñóäèòü ñ ãåíåòèêîì ïîèñê âûøåóêàçàíí. ñèíäðîìa
34 different ATP1A3 mutations were detected in 85 % (132/155) patients, 7 of which were novel. In general, mutations were found to cluster into five different regions. The most frequent mutations included: p.Asp801Asn (43 %; 57/132), p.Glu815Lys (16 %; 22/132), and p.Gly947Arg (11 %; 15/132). Of these, p.Glu815Lys was associated with a severe phenotype, with more severe intellectual and motor disability. p.Asp801Asn appeared to confer a milder phenotypic expression, and p.Gly947Arg appeared to correlate with the most favourable prognosis, compared to the other two frequent mutations. Overall, the comparison of the clinical profiles suggested a gradient of severity between the three major mutations with differences in intellectual (p = 0.029) and motor (p = 0.039) disabilities being statistically significant. For patients with epilepsy, age at onset of seizures was earlier for patients with either p.Glu815Lys or p.Gly947Arg mutation, compared to those with p.Asp801Asn mutation (p < 0.001).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #20  
Ñòàðûé 26.06.2018, 10:20
AlenaP2018 AlenaP2018 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 21.06.2018
Ãîðîä: Åêàòåðòíáóðã
Ñîîáùåíèé: 13
Ñêàçàë(à) ñïàñèáî: 2
AlenaP2018 *
Öèòàòà:
Ñîîáùåíèå îò Dr.Vad Ïîñìîòðåòü ñîîáùåíèå
êàê æå âû ÷èòàëè/ïîíÿëè, åñëè çàäàåòå òàêèå âîïðîñû, êîãäà â òåêñòå:

Molecular genetic testing for mutations in the ATP1A3 gene is available on a clinical basis via individual targeted gene sequencing or as part of larger gene panels. Increasingly, ATP1A3 mutations are identified in the context of clinical exome sequencing.



34 different ATP1A3 mutations were detected in 85 % (132/155) patients, 7 of which were novel. In general, mutations were found to cluster into five different regions. The most frequent mutations included: p.Asp801Asn (43 %; 57/132), p.Glu815Lys (16 %; 22/132), and p.Gly947Arg (11 %; 15/132). Of these, p.Glu815Lys was associated with a severe phenotype, with more severe intellectual and motor disability. p.Asp801Asn appeared to confer a milder phenotypic expression, and p.Gly947Arg appeared to correlate with the most favourable prognosis, compared to the other two frequent mutations. Overall, the comparison of the clinical profiles suggested a gradient of severity between the three major mutations with differences in intellectual (p = 0.029) and motor (p = 0.039) disabilities being statistically significant. For patients with epilepsy, age at onset of seizures was earlier for patients with either p.Glu815Lys or p.Gly947Arg mutation, compared to those with p.Asp801Asn mutation (p < 0.001).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Ìû èìåëëè ââèäó ïîìèìî ýòîãî àíàëèçà ,÷òî åùå ìîæíî ñäàòü ,îí âñå-òàêè ïðèìåðíî 3ìåñ ãîòîâèòñÿ,
Îòâåòèòü ñ öèòèðîâàíèåì
  #21  
Ñòàðûé 26.06.2018, 14:18
annadrobitova annadrobitova âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.06.2011
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,607
Ñêàçàë(à) ñïàñèáî: 17
Ïîáëàãîäàðèëè 1,149 ðàç(à) çà 1,121 ñîîáùåíèé
annadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äðóãèõ ñïåöèôè÷åñêèõ àíàëèçîâ ÿ íå íàøëà
Ôëóíàðèçèí ó íàñ íå çàðåãèñòðèðîâàí, íî íå çàïðåùåí, ìîæíî ïðîáîâàòü, ÿ äóìàþ, íå äîæèäàÿñü àíàëèçà
Îñòàëüíûå âîçìîæíûå ïðè÷èíû óæå èñêëþ÷åíû
Îòâåòèòü ñ öèòèðîâàíèåì
  #22  
Ñòàðûé 26.06.2018, 18:28
AlenaP2018 AlenaP2018 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 21.06.2018
Ãîðîä: Åêàòåðòíáóðã
Ñîîáùåíèé: 13
Ñêàçàë(à) ñïàñèáî: 2
AlenaP2018 *
Öèòàòà:
Ñîîáùåíèå îò annadrobitova Ïîñìîòðåòü ñîîáùåíèå
Äðóãèõ ñïåöèôè÷åñêèõ àíàëèçîâ ÿ íå íàøëà
Ôëóíàðèçèí ó íàñ íå çàðåãèñòðèðîâàí, íî íå çàïðåùåí, ìîæíî ïðîáîâàòü, ÿ äóìàþ, íå äîæèäàÿñü àíàëèçà
Îñòàëüíûå âîçìîæíûå ïðè÷èíû óæå èñêëþ÷åíû
Ó íàñ â Åêàòåèíáóðãå íèãäå íåò ýòîãî ïðåïàðàòà,áóäåì ïûòàòüñÿ äîñòàòü, à îí â êâîòó íå âõîäèò â äåòñêèõ ïîëèêëèíèêàõ?
Êàê ðàñ÷èòàòü äîçèðîâêó ? Ðåáåíêó ãîä è ìåñÿö âåñèò îðèåíòèðîâî÷íî 9800 - 10 êã , åñòü ëè îò íåãî ñîíëèâîñòü? Òîðìîçèò ëè ðàçâèòèå ðåáåíêà?
Îòâåòèòü ñ öèòèðîâàíèåì
  #23  
Ñòàðûé 27.06.2018, 08:47
AlenaP2018 AlenaP2018 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 21.06.2018
Ãîðîä: Åêàòåðòíáóðã
Ñîîáùåíèé: 13
Ñêàçàë(à) ñïàñèáî: 2
AlenaP2018 *
Öèòàòà:
Ñîîáùåíèå îò annadrobitova Ïîñìîòðåòü ñîîáùåíèå
1. Ñîãëàñíà ñ êîëëåãîé, â ìîìåíò ïðèñòóïà íóæíî èññëåäîâàòü ÝÝÃ, K, Na, Cl
2. Îáñóäèòü ñ ãåíåòèêîì ïîèñê íàðóøåíèé îáìåíà è âûøåóêàçàííûé ñèíäðîì
3. ÌÐÒ ãîëîâíîãî ìîçãà

à ýòî ýýã ðóòèííîå
Ìèíèàòþðû
Íàæìèòå íà èçîáðàæåíèå äëÿ óâåëè÷åíèÿ
Íàçâàíèå: ÝÝÃ 2,08,2017.jpg
Ïðîñìîòðîâ: 6
Ðàçìåð:	73.1 Êá
ID:	161031  
Îòâåòèòü ñ öèòèðîâàíèåì
  #24  
Ñòàðûé 27.06.2018, 08:49
AlenaP2018 AlenaP2018 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 21.06.2018
Ãîðîä: Åêàòåðòíáóðã
Ñîîáùåíèé: 13
Ñêàçàë(à) ñïàñèáî: 2
AlenaP2018 *
Öèòàòà:
Ñîîáùåíèå îò eqimi Ïîñìîòðåòü ñîîáùåíèå
Âàø ñëó÷àé ñëîæíûé.
Äëÿ íà÷àëà âûëîæèòå ðåçóëüòàòû ÝÝà ãäå èìåþòñÿ ýïèëåïòèôîðìíûå èçìåíåíèÿ.
Ðåçóëüòàòû ÌÐÒ.
Âòîðîé è î÷åíü âàæíûé ïîäõîä --- äàæå åñëè èíòåðèêòàëüíàÿ ÝÝÃ, õîòü áîäñòðâîâàíèå èëè ñîí íå ïîêàçûâàþò èçìåíåíèé ýòî íå çíà÷èò ÷òî âñ¸ â ïîðÿäêå.  äàííîì ñëó÷àå â âàøåì îïèñàíèè êàê ìèíèìóì 3 äâèæåíèÿ êîòîðûå çàñëóæèâàþò äîëæíîãî âíèìàíèÿ è äåòàëüíîãî èçó÷åíèÿ.

Îáúÿçàòåëüíî çàïèñàòü èêòàëüíîå ÝÝÃ, ïî âîçìîæíîñòè ïîéìàòü âî âðåìÿ çàïèñè ÝÝÃ äàííûå äâèæåíèÿ.

Ñ óâàæåíèåì,


âîò ÝÝÃ äåëàëè ïðè ãîñïèòàëèçàöèè
Ìèíèàòþðû
Íàæìèòå íà èçîáðàæåíèå äëÿ óâåëè÷åíèÿ
Íàçâàíèå: ÝÝÃ 2,08,2017.jpg
Ïðîñìîòðîâ: 6
Ðàçìåð:	73.1 Êá
ID:	161036  
Îòâåòèòü ñ öèòèðîâàíèåì
  #25  
Ñòàðûé 27.06.2018, 15:35
annadrobitova annadrobitova âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.06.2011
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,607
Ñêàçàë(à) ñïàñèáî: 17
Ïîáëàãîäàðèëè 1,149 ðàç(à) çà 1,121 ñîîáùåíèé
annadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåannadrobitova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ß æå íàïèñàëà, ÷òî â ÐÔ ïðåïàðàò íå çàðåãèñòðèðîâàí
Îòâåòèòü ñ öèòèðîâàíèåì
  #26  
Ñòàðûé 29.06.2018, 05:14
AlenaP2018 AlenaP2018 âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 21.06.2018
Ãîðîä: Åêàòåðòíáóðã
Ñîîáùåíèé: 13
Ñêàçàë(à) ñïàñèáî: 2
AlenaP2018 *
Ïàïêà èç Îáëàêà Mail.Ru
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Äîáðîå óòðî! äîáàâèëè íîâûå ðåçóëüòàòû àíàëèçîâ : cl, ãåðïåñ 6ãî òèïà, ÒÒÃ , ñò3,ñò4, îáùèé àíàëèç êðîâè.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 01:23.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.